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Abstract
Introduction. Dilated cardiomyopathy (DCM) and myxomatous mitral valve disease (MMVD) are common 
heart conditions in dogs. They have different etiology and pathogenesis and although other studies focused on 
changes in the left ventricles of the affected hearts, the aim of our study was to assess the expressions of some 
intrinsic proteins in the enlarged left atria. 
Material and methods. We performed an immunohistochemical analysis of left atrial specimens obtained from 
15 dogs with DCM, 35 dogs with MMVD and six control dogs. We assessed the expression of following proteins: 
SERCA1, SERCA2, sarcomeric actinin, smooth muscle actin, and dystrophin.
Results. We noted a higher percentage of SERCA1-positive cells in the MMVD group and lower percentage 
of dystrophin-positive cells in the DCM group as compared to control group. The expression of other proteins 
was similar in the hearts of control dogs and dogs with heart diseases. 
Conclusions. The observed changes in the expression patterns of some proteins in the atria of dogs with DCM 
and MMVD suggest that atrial enlargement relies not only on volume overload, but also alterations of the intrin-
sic proteins can contribute to the pathogenesis of dilated cardiomyopathy. (Folia Histochemica et Cytobiologica 
2017, Vol. 55, No. 2, 52–61)
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Introduction
Dilated cardiomyopathy (DCM) and myxomatous 
mitral valve disease (MMVD) are the most common 
cardiac disorders in large (DCM) or small (MMVD) 
breed dogs. They are both accompanied by heart 
enlargement, including mostly left ventricle and 
left atrium, although the pathomechanisms of these 
changes seem to vary between both diseases [1–5]. 
MMVD involves a progressing degeneration of mitral 
valve leaflets, which results in an increased mitral 
regurgitation blood flow. These changes directly 
lead to heart remodeling which particularly involves 
the left atrium [5]. The mechanism of left ventricular 
and left atrial enlargement in DCM is complex and 
probably does not result mainly from the chamber 
volume overload, although has not yet been well de-
fined. Various factors like structural protein defects 
or impaired tissue oxygen supply are suspected to play 
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a role in this process [4]. The majority of studies on 
heart failure resulting from these diseases focuses on 
changes occurring in the heart ventricles. However, 
current research suggests that myocardial remodeling 
occurs not only in the ventricle, but may be even more 
pronounced in atrial tissue [6–7].
During heart failure various myocardial proteins (in-
cluding proteins of cardiomyocyte and extracellular ma-
trix) present altered expression in heart muscle [8–11]. 
Atrial tissue undergoes different remodeling, as com-
pared to ventricular cardiac muscle in various heart 
diseases, including DCM and congestive heart failure 
associated with arrhythmia [6, 12, 13].
Our previous study [11] showed that in dogs with 
congestive heart failure and left atrial enlargement 
various myocardial proteins undergo changes in their 
expression in left atrial myocardium. Based on that 
preliminary study we decided to further explore the 
alterations in the left atrial cardiomyocytes during 
heart failure due to DCM and MMVD, including the 
expression of sarcoplasmic reticulum Ca2+ ATPase 
2A-1 (SERCA1) protein, sarcoplasmic reticulum Ca2+ 
ATPase 2A-2 (SERCA2) protein, sarcomeric alpha- 
-actinin (SA), alpha-smooth muscle actin (SMA), and 
dystrophin (DMD).
Sarcoplasmic reticulum Ca2+ ATPases are responsi-
ble for maintaining a sufficient cytosolic Ca2+ concentra-
tion during muscle contraction-relaxation cycles [14, 15]. 
SERCA2 is the major isoform expressed in adult 
mammalian heart with higher protein level in atria as 
compared to the ventricles [14, 15]. The chamber-re-
lated changes in protein expression may be connected 
with shorter duration of cardiomyocytes’ contraction 
in atria than in ventricles [14]. The decrease in SER-
CA2 levels is associated with impaired myocardial 
function [14, 15]. SERCA1 is the isoform expressed 
mainly in skeletal muscles. However, there is evidence 
that its expression is altered in failing myocardium 
in humans and animals, changing the rate of Ca2+ 
transport [15, 16]. The changes in SERCA expression 
might be a part of a natural adaptive process in the 
failing heart [16].
Cardiac alpha actin and skeletal muscle alpha actin 
are the major sarcomeric actin isoforms detected in 
striated muscles [17]. Smooth muscle actin produces 
a strong cytoplasmic staining in most smooth muscle 
cells, including those that form blood vessels [18]. 
In normal cardiac tissue the staining for SMA is re-
stricted to smooth muscle cells of the vascular walls, 
whereas the cardiomyocytes are clearly negative [18]. 
During heart failure the amount of SMA-positive cells 
increases [19].
Dystrophin belongs to a group of membrane-as-
sociated proteins. Along with spectrin, talin, vinculin 
and ankyrin, it is involved in the fixation of sarcom-
eres to sarcolemma and stabilization of the plasma 
membrane [8, 20]. A dystrophin missense mutation 
may cause X-linked dilated cardiomyopathy in both 
humans and dogs. In the disease, the heart muscle 
is mechanically weak and the contraction of the cell 
leads to membrane damage, muscle necrosis and 
degeneration [8, 20–22]. Apart from being a cause 
of muscle diseases, DMD was also found to be 
down-regulated in consequence of myocardial injury 
and ischemia of various origins [23, 24].
The aim of the study was to determine the expres-
sion of SERCA1, SERCA2, SA, SMA, and DMD 
proteins in left atrial tissue of dogs with dilated 
cardiomyopathy or myxomatous mitral valve disease.
Material and methods
Population study and inclusion criteria. The study was con-
ducted on left atrial specimens obtained from 56 dogs divided 
into 3 groups: dogs presenting with dilated cardiomyopathy 
(DCM group; n = 15), dogs with left atrial enlargement due 
to myxomatous mitral valve disease (MMVD group; n = 35) 
and dogs that underwent euthanasia due to causes not related 
to cardiovascular system and that did not show intravital or 
post-mortem features of cardiorespiratory disease and left 
atrial (LA) enlargement (control group; n = 6).
Dogs met the inclusion criteria if they had an enlarged 
left atrium as defined by an echocardiographic examination 
(left atrial (LA)-to-aortic root (Ao) diameter ratio; LA/ 
/Ao > 1.7 [1]), which was confirmed by the post-mortem 
examination. A dilation of the left ventricle and a decreased 
fractional shortening (FS < 20%), both noted during the 
echocardiographic examination [2, 4, 25], with normal or 
type 1 mitral valve lesions noted in autopsy (according to 
Whitney [26]) were required to classify dogs in the DCM 
group. Dogs in the MMVD group were required to have a 
preserved left ventricular systolic function (FS > 20% as 
revealed by echocardiographic examination) with type 3 
or 4 mitral valve lesions (according to Whitney [26], found 
during autopsy). At the time of death or euthanasia, all 
the dogs in the DCM and MMVD groups presented with 
stage D heart failure (according to the ACVIM Consensus 
Statement [27]).
Clinical and post-mortem examination. Forty dogs under-
went a standard clinical and cardiological examination with 
ECG, an echocardiographic examination and 24-hour ECG 
(Holter) monitoring in cases where rhythm disturbances 
were suspected as described in our previous study [11]. After 
the examination, dogs in the DCM and the MMVD group 
underwent appropriate treatment to reduce the effects 
of progressive heart failure and/or arrhythmias, and were 
checked every 6 months or more frequently if necessary 
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until the moment of death or euthanasia. All the dogs in 
the DCM and the MMVD group died or were euthanized 
within five years of diagnosis.
In 16 cases, some or all the results of the cardiac exami-
nation were not available. In those cases, a particular empha-
sis was put on the post-mortem examination to confirm the 
inclusion of the dogs in the DCM, MMVD, or control group.
The results of the echocardiographic examination (left 
atrial and left ventricular enlargement) were confirmed 
during the autopsy, and the type of mitral valve lesion was 
assessed. Heart measurements were taken using a manual 
150 mm Beerendonk caliper, accurate to the nearest 1/20 
mm. The measurements were taken in planes compatible 
with those used during the echocardiographic examination. 
The left atrial diameter was related to the diameter of the 
aorta (as in LA/Ao ratio) and the left ventricular internal 
diameter and wall thickness were measured beneath the mi-
tral valve between the papillary muscles. The type of mitral 
valve lesion according to Whitney [26] was determined based 
on the thickness of the valve leaflets and tendinous chords. 
Specimens from the left atrial wall were collected from each 
dog for further histopathological and immunohistochemical 
analyses. The specimens were collected in the dorso-ventral 
plane from the middle portion of the atrial free wall, at the 
same site in all the dogs.
Histopathological examination. The specimens were fixed 
in 7% buffered formalin, dehydrated, embedded in paraffin 
blocks and sectioned at 4 μm. Each specimen was randomly 
assigned a number to allow a blinded examination. The spec-
imens were stained with hematoxylin-eosin or Masson-Gold-
ner trichrome methods and evaluated for interstitial and 
perivascular fibrosis, cardiomyocyte degeneration (including 
cardiomyocyte nuclei enlargement, loss of cross striation and 
altered cardiomyocyte structure), intramyocardial arterial 
narrowing and inflammatory infiltrates as described in our 
previous studies [11, 12]. Each of the features was evaluated 
in 20 randomly chosen fields per slide (for interstitial fibrosis, 
cardiomyocyte degeneration and inflammatory infiltrates) 
or in at least 10 vessels per slide (for perivascular fibrosis 
and intramyocardial arterial narrowing). An average score 
was counted for each feature in every specimen as described 
previously [11, 12].
Immunohistochemical examination. The paraffin sections 
were placed on silanized microscopic slides and underwent 
a standardized immunohistochemical (IHC) staining pro-
cedure. The sections were overlaid with primary antibodies, 
including a mouse monoclonal anti-ATP2A-1 — clone 4B8 
(dilution 1:600, SERCA1 protein; Sigma-Aldrich, St. Louis, 
MO, USA), a rabbit polyclonal anti-ATP2A-2 (dilution 
1:800, SERCA2 protein; Sigma-Aldrich), a mouse monoclo-
nal anti-alpha-actinin (sarcomeric) — clone EA-53 (dilution 
1:500, specific for both alpha-skeletal muscle and alpha-car-
diac muscle actinin Sigma-Aldrich), a mouse monoclonal 
anti-alpha-smooth muscle actin — clone 1A4 (Sigma- 
-Aldrich; dilution 1:1000); a rabbit polyclonal anti-DMD 
(dilution 1:1000; Sigma-Aldrich). The slides were incubated 
for 20 min with EnVision FLEX/HRP (DAKO, Glostrup, 
Denmark). 3,3’-diaminobenzidine (DAB) was used as the 
peroxidase substrate and the sections were incubated for 
10 min. Finally, all sections were counterstained for 5 min 
with EnVision FLEX Hematoxylin (Dako). Specimens from 
uterus, gastrointestinal tract, urinary bladder and skeletal 
muscles served as positive controls for the expression of 
smooth muscle and skeletal muscle markers; sections immu-
nostained in the absence of a primary antibody were used 
as negative controls.
Photomicrographs of the examined tissues were subject-
ed to computer-assisted image analysis, using a computer 
coupled to an optical Olympus BX53 microscope, equipped 
with an Olympus Color View IIIu digital camera (Olympus, 
Tokyo, Japan) and Cell^A software (Olympus Soft Imaging 
Solution GmbH, Berlin, Germany).
To allow a semi-quantitative comparison of the exam-
ined markers and their correlation with myocardial remod-
eling, their expression in cardiomyocyte was appraised in 
10 randomly chosen high power fields (total magnification 
×400) using a two-step approach: 1) the intensity of reaction 
(using the following scoring system: 0 — no reaction; 1 — 
mild reaction; 2 — moderate reaction; 3 — strong reaction), 
2) the percentage of marker-positive cells within a high 
power field (×400). An average score from 10 examined 
fields was counted for each feature.
Statistical analysis. The normality of the data was evaluated 
using Shapiro-Wilk analysis. The obtained data underwent 
statistical analysis using the Kruskal-Wallis rang analysis and 
Spearman’s correlation test using StatisticaPL for Windows 
(StatSoft, Cracow, Poland). Statistical significance was set 
at p ≤ 0.05.
Results
The population study of examined dogs is presented in 
Table 1. The DCM group consisted of eight Doberman 
Pinchers, four German Shepherds, one boxer, one Great 
Dane, and one Caucasian Shepherd Dog. The MMVD 
group included 23 mixed-breed dogs, six dachshunds, 
two miniature Pinchers and one dog of each breed: Black 
Russian Terrier, Shar-Pei, Cairn Terrier and the Amer-
ican Staffordshire Terrier. The control group consisted 
of three mixed-breed dogs and one dog of each breed: 
Dachshund, Boxer, Yorkshire Terrier.
There was no significant difference between the 
LA/Ao ratio in DCM and MMVD groups in either 
the echocardiographic or post-mortem examination 
(p > 0.05).
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The results of histopathological examination are 
presented in Table 2. Specimens from the control 
group showed no or slight histopathological changes. 
LA tissue from dogs in the DCM and MMVD groups 
showed signs of remodeling (including interstitial and 
perivascular fibrosis, fatty infiltration and features 
of cardiomyocyte degeneration). Moreover, speci-
mens in the DCM group showed lower perivascular 
fibrosis score, higher interstitial fibrosis score and 
higher values of cardiomyocyte degeneration features 
(abnormal cell nuclei, loss of striation and altered 
cardiomyocyte structure) as compared to specimens 
from the MMVD group.
Table 1. Population study of the examined dogs
DCM group (n = 15) MMVD group (n = 35) Control group (n = 6)
Sex (n)
M 13 24 3
F 2 11 3
Age (years)
Mean ± SD 8.37 ± 2.39 13.14 ± 2.96 7.63 ± 4.6
Min–max 4–11 8–19 1–12
Body mass [kg]
Mean ± SD 35 ± 6.43 13.17 ± 7.77 9.05 ± 10.78
Min–max 31–45 5–35 1.5–25
LA/Ao Mean ± SD 3.14 ± 0.33 2.76 ± 0.65 1.03 ± 0.23
DCM group — dogs with dilated cardiomyopathy; MMVD group — dogs with myxomatous mitral valve disease; M — male; F — female; 
SD — standard deviation; min — minimal value; max — maximal value; LA/Ao — left atrial-to-aortic root ratio.
Table 2. Histopathological characteristics of the studied groups of dogs
DCM group (n = 15) MMVD group (n = 35) Control group (n = 6)
Interstitial fibrosis (median; range) 4 (2–7) 2 (0–6) 0 (0–1)
Perivascular fibrosis (median; range) 1 (0–2) 2 (1–2) 0 (0–1)
Fatty infiltration (median; range) 2 (0–10) 1 (0–6) 0 (0–2)
LAR (median; range) 0.35 (0.13–0.61) 0.28 (0.13–0.45) 0.32 (0.15–0.35)
Abnormal cell nuclei (median; range) 2 (1–3) 1 (0–3) 0 (0–1)
Loss of striation (median; range) 3 (1–3) 1 (0–3) 0 (0–1)
Altered cardiomyocyte structure (median; range) 3 (2–3) 1 (0–3) 0 (0–1)
Inflammatory infiltration (median; range) 0.6 (0–1.6) 0.33 (0–2.1) 0 (0–1.6)
DCM group — dogs with dilated cardiomyopathy; MMVD group — dogs with myxomatous mitral valve disease; LAR — lumen area ratio: the 
luminal area of the vessel divided by the total vessel area excluding adventitia.
Table 3. The percentages of protein-immunoreactive cells in the examined groups of dogs
DCM group (n = 15) MMVD group (n = 35) Control group (n = 6)
SERCA1 (%) (mean ± SEM) 35.01 ± 8.46 35.61 ± 5.08* 14.45 ± 14.45
SERCA2 (%) (mean ± SEM) 59.51 ± 10.62 80.77 ± 3.96 88.75 ± 3.41
SA (%) (mean ± SEM) 41.61 ± 8.87 42.77 ± 5.33 59.8 ± 20.6
SMA (%) (mean ± SEM) 36.1 ± 9.2 11.73 ± 2.17 3.63 ± 0.91
DMD (%) (mean ± SEM) 19,18 ± 7.06* 40.36 ± 6.52 69.57±11.52
DCM group — dogs with dilated cardiomyopathy; MMVD group — dogs with myxomatous mitral valve disease; SERCA1 — sarcoplasmic reticulum 
Ca2+ ATPase 2A-1; SERCA2 — sarcoplasmic reticulum Ca2+ ATPase 2A-2; SA — sarcomeric alpha-actinin; SMA — alpha-smooth muscle actin; 
DMD — dystrophin; SEM — standard error of mean. *Significantly different from control.
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The summary of the results of the IHC investigations 
is shown in Table 3 and the examples of the immu-
noreactivity of the studied proteins are presented in 
Figures 1–5. 
SERCA1 and SERCA2
The expression of SERCA1 protein showed a cyto-
plasmic pattern in 67% of specimens in the DCM 
group and 74% of specimens in the MMVD group. 
Two specimens (33.3%) from a control group showed 
a positive expression of this protein.
There were no significant differences in the inten-
sity of expression of SERCA1-immunopostive cells in 
the examined groups (p > 0.05). There was a signifi-
cantly higher percentage of SERCA1-positive cells in 
the MMVD group as compared to the control group 
(p = 0.05; Tab. 3; Fig. 1). No correlation between 
SERCA1 immunoreactivity and histological evidence 
of myocardial remodeling was found (p > 0.05).
The expression of SERCA2 protein showed a cyto-
plasmic pattern in all specimens in control group, 67% 
of specimens in the DCM group, and 94% of speci-
mens in the MMVD group. There were no significant 
differences in the intensity of immunoreactivity and 
percentage of SERCA2-positive cells in the examined 
groups (p > 0.05; Tab. 3; Fig. 2).
There was a weak negative correlation between 
the percentage of SERCA2-positive cells and cardio-
myocyte nuclei enlargement (p < 0.05; r = –0.33) and 
cardiomyocyte degeneration (p < 0.05; r = –0.29). We 
found no correlation between SERCA2 immunore-
activity and other histological evidence of myocardial 
remodeling (p > 0.05).
Sarcomeric actinin and SMA
The expression of SA showed a cytoplasmic pattern 
in 67% of specimens in the control group, 73% of 
specimens in the DCM group, and 83% of specimens 
in the MMVD group. There were no significant dif-
ferences in the intensity of expression and percentage 
of striated muscle actin-immunoreactive cells between 
the examined groups (p > 0.05; Tab. 3; Fig. 3). We 
found no correlation between striated muscle actin 
expression and histological evidence of myocardial 
remodeling (p > 0.05).
The immunoexpression of the SMA protein 
showed a cytoplasmic pattern in less than 6% of car-
diomyocytes in all specimens in the control group, 
a cytoplasmic pattern of various extents in 80% of speci - 
mens in the DCM group, and 89% of specimens in the 
MMVD group. There was no significant difference 
in the intensity of expression of this protein or per-
centage of SMA-positive cells in all groups (p > 0.05; 
Tab. 3; Fig. 4).
There was a weak positive correlation of percent-
age of SMA-positive cells with cardiomyocyte nuclei 
enlargement (p < 0.05; r = 0.3) and cardiomyocyte 
degeneration (p < 0.05; r = 0.27). We found no cor-
Figure 1. The expression of sarcoplasmic reticulum Ca2+ 
ATPase 2A-1 (SERCA1) in heart’s atria of the examined 
groups of dogs. The immunoreactivity (IR) of SERCA1 was 
present in cardiomyocytes’ cytoplasm (arrows). A. MMVD 
group, IR scored 1; B. DCM group, IR scored 1; C. Control 
group, IR scored 1. Abbreviations as in the description of 
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Figure 2. The expression of sarcoplasmic reticulum Ca2+ ATPase 
2A-2 (SERCA2) in heart’s atria of the examined groups of 
dogs. The IR of SERCA1 was present in cardiomyocytes’ 
cytoplasm (arrows). A. MMVD group, cardiomyocytes are 
swollen, IR scored 2; B. DCM group, cardiomyocytes show 
disarrangement and irregular SERCA2 reactivity, IR scored 1; 
C. Control group, IR scored 2. Abbreviations as in the de-
scription of Figure 1. Magnification ×400. 
Figure 3. The expression of sarcomeric alpha-actinin (SA) in 
heart’s atria of the examined groups of dogs. The IR of SA was 
present in cardiomyocytes’ cytoplasm (arrows). A. MMVD 
group, IR scored 1; B. DCM group, IR scored 2; C. Control 
group, IR scored 1. Abbreviations as in the description of 
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Figure 4. The expression of alpha-smooth muscle actin (SMA) 
in heart’s atria of the examined groups of dogs. The IR of 
SMA was present in cardiomyocytes’ cytoplasm (arrows). As-
terisks (*) show blood vessels with strong positive expression 
of the SMA (internal positive control). A. MMVD group, 
irregular diffuse expression of SMA protein, IR scored 1; 
B. DCM group, irregular diffuse expression of SMA, IR scored 1; 
C. Control group, clear and visible expression of SMA in 
blood vessels (*) with cardiomyocyte negative for the exam-
ined protein. IR scored 1. Abbreviations as in the description 




Figure 5. The expression of dystrophin (DMD) in heart’s 
atria of the examined groups of dogs. The IR of dystrophin 
was present in cardiomyocytes’ cell membranes (arrows). 
A. MMVD group, IR scored 1; B. DCM group, IR scored 1; 
C. Control group, IR scored 2. Abbreviations as in the de-
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Shepherd dogs with DCM as compared to normal 
canine myocardium. Lack of significant difference 
between the DCM and control groups in our study 
may be due to the heterogeneity of the DCM group 
(apart from German Shepherds, also Dobermans, 
Boxer dog and Caucasian Shepherd were included). 
In the aforementioned study [16], authors noted also 
that the expression of SERCA1 protein was heteroge-
neous and varied regionally in the specimens obtained 
from right ventricle, left ventricle and interventricular 
septum. However, they did not examine specimens 
from atrial walls, what was the subject of our study.
Smooth muscle proteins, including smooth muscle 
alpha-actin, show higher content in specimens from 
human patients with DCM as compared to normal 
hearts [19]. We found no significant differences 
between the examined groups in the percentage of 
SMA-positive cells, although we observed a trend of 
higher SMA-positive cells percentage in the DCM and 
MMVD groups, as compared to the control group. 
Interestingly, in all of the specimens from the control 
group, less than 6% of cardiomyocyte showed positive 
reaction to SMA. 
We did not notice differences between the per-
centage of sarcomeric actinin-positive cells between 
the control group and the DCM and MMVD groups, 
although Driesen et al. [17] reported a re-expression of 
alpha-skeletal muscle actin with a down-regulation of 
alpha-cardiac actin in various types of heart diseases. 
As the antibody used in our study did not allow us to 
make recognition between alpha-cardiac actin and al-
pha-skeletal muscle actin, we cannot confirm whether 
such transformation is present in dogs with end-stage 
DCM and MMVD. An over-regulation of alpha-skel-
etal muscle actin could disguise a down-regulation of 
alpha-cardiac actin in the examined material. This 
issue should be a topic of further investigation.
Dystrophin is a membrane-associated protein that 
plays a role in preserving the cardiomyocyte contrac-
tile function [8, 20]. Its expression is down-regulated 
in various diseases, including dystrophinopathies 
and ischemic heart disease [8, 20–24]. In contrary 
to the results obtained by Spier et al. [28], we noted 
a lower staining intensity and percentage of DMD- 
-immunoreactive cells in the DCM dogs as compared 
to control group. Although the dogs in our study 
did not undergo genetic examination, none of the 
dogs in the DCM group presented with progressing 
skeletal muscle weakness. That allows us to exclude 
inherited dystrophinopathy as a direct cause of DCM 
and observed down-regulation of DMD expression 
in the examined specimens. Although there was no 
significant difference between the MMVD and con-
trol groups in dystrophin immunoreactivity, a visible 
relation between SMA reaction and other histological 
evidence of myocardial remodeling (p > 0.05).
Dystrophin
Dystrophin immunoreactivity showed a membranous 
pattern in all specimens in the control group, in 40% 
of specimens in the DCM group, and in 57% of spec-
imens in the MMVD group. The intensity of the im-
munoreactivity of dystrophin was significantly higher 
in the control group as compared to the DCM group 
(p = 0.02). The percentage of DMD-immunopositive 
cells was significantly lower in the DCM group, as 
compared to control group (p = 0.02; Tab. 3; Fig. 5).
There was a mild negative correlation between the 
percentage of DMD-positive cells and features of myo - 
cardial damage: cardiomyocyte nuclei enlargement 
(p < 0.05; r = –0.42), cardiomyocyte degeneration 
(p < 0.05; r = –0.43), and loss of cardiomyocyte stri-
ation (p < 0.05; r = –0.38). We found no correlation 
between dystrophin immunoreactivity and other histo-
logical evidence of myocardial remodeling (p > 0.05).
Discussion
The expression of various cardiomyocyte proteins 
in left atria of dogs is altered in heart failure, as was 
noted in this study and previous studies [6, 11–13]. 
Although the majority of studies on SERCA2 ex-
pression in heart failure point to a decrease in the 
protein level, in some studies, the expression levels 
of SERCA2 was found to be unaltered, similarly to 
our results [14, 16]. Regardless the unchanged level 
of SERCA2 expression, sarcoplasmic reticulum Ca2+ 
transport function may be decreased [14]. As there is 
a considerable heterogeneity in the expression level of 
SERCA in the failing heart, the differences between 
the obtained results can be explained by a variety of 
factors, including animal model studied, methodolog-
ical differences, severity of the disease, treatment, age 
and gender [14]. It is also possible, that the changes 
in Ca2+ transport occurring in the ventricles during 
heart failure are not so prominent in the atria, despite 
the higher level of SERCA protein in normal atrial 
myocardium as compared to the ventricles [14].
We found no significant differences in the SER-
CA2 immunoreactivity between the examined groups; 
however, there was a higher percentage of SER-
CA1-positive cells in the MMVD group as compared 
to the control group. As mentioned before, SERCA1 
may undergo expression in myocardium as a part of 
a natural adaptive process in the failing heart [15, 16]. 
Our results are partially consistent with the results 
obtained by Summerfield et al. [16] who noticed 
a higher expression of SERCA1 protein in German 
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trend of concomitant down-regulation of dystrophin 
also in the MMVD group and a negative correlation 
between dystrophin reactivity and features of cardi-
omyocyte damage were observed. It may suggest that 
in both DCM and MMVD, atrial tissue is exposed to 
various stress factors, including ischemia, which can 
cause loss of dystrophin in cardiomyocytes [23–24]. 
Nonetheless, a significance noted only in the DCM 
group as compared to control dogs suggests that in 
this disease decreased DMD immunoexpression may 
be connected not only to cardiac remodeling due to 
volume overload, but also to other pathomechanisms 
including protein alterations. 
Conclusions
Dilated cardiomyopathy and myxomatous mitral 
valve disease are both accompanied by left atrial en-
largement. In our study on dogs we have noted that 
some changes occurring in the immunoexpression 
of proteins building atrial tissue in both diseases are 
similar; however, there are also significant differences. 
These findings suggest that other mechanisms, except 
for volume overload, may be involved in left atrial 
enlargement in those two diseases. Understanding the 
mechanisms underlying those diseases may help in the 
treatment and extend life span of the affected dogs.
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